Asthma iN children: omalizumab in real-life in spain (ANCHORS study). omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma - Nieto Garcia, A; Garriga Baraut, T; Plaza Martin, A M; Nieto Cid, M; Torres Borrego, J; Folque Gimenez, M M; Lozano Blasco, J; Bosque Garcia, M; Moreno Galarraga, L; Tortajada Girbes, M; Rivas Juesas, C; Penin Anton, M; et al. (ALLERGY, 2021)